XML 258 R214.htm IDEA: XBRL DOCUMENT
v3.22.4

Segment information - Summary of Net Sales by Segment and Geographical Area (Details) - EUR (€) € in Millions | 12 Months Ended
--- | ---
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Disclosure of geographical areas [line items] |  |  |  |
Net sales | € 42,997 | € 37,761 | € 36,041 | [1]
Pharmaceuticals |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 30,688 | 26,970 | 25,674 |
Pharmaceuticals | Dupixent |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 8,293 | 5,249 | 3,534 |
Pharmaceuticals | Neurology & Immunology |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 2,450 | 2,324 | 2,394 |
Pharmaceuticals | Aubagio |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 2,031 | 1,955 | 2,045 |
Pharmaceuticals | Rare Diseases |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 3,445 | 3,126 | 3,011 |
Pharmaceuticals | Cerezyme |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 707 | 683 | 690 |
Pharmaceuticals | Fabrazyme |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 938 | 844 | 817 |
Pharmaceuticals | Myozyme/Lumizyme |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 958 | 1,003 | 948 |
Pharmaceuticals | Oncology |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 952 | 912 | 798 |
Pharmaceuticals | Jevtana |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 391 | 455 | 536 |
Pharmaceuticals | Rare Blood Disorders |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 1,317 | 1,141 | 1,217 |
Pharmaceuticals | Alprolix |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 504 | 414 | 466 |
Pharmaceuticals | Eloctate |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 580 | 563 | 638 |
Pharmaceuticals | Core Assets |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 6,389 | 5,768 | 5,581 |
Pharmaceuticals | Lovenox |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 1,310 | 1,486 | 1,351 |
Pharmaceuticals | Toujeo |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 1,117 | 969 | 933 |
Pharmaceuticals | Plavix |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 983 | 929 | 913 |
Pharmaceuticals | Non-Core Assets |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 7,222 | 7,642 | 8,326 |
Pharmaceuticals | Lantus |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 2,259 | 2,494 | 2,661 |
Pharmaceuticals | Other non-core assets |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 4,485 | 4,729 | 5,111 |
Pharmaceuticals | Industrial sales |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 620 | 808 | 813 |
Vaccines |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 7,229 | 6,323 | 5,973 |
Vaccines | Polio/Pertussis/ Hib Vaccines |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 2,285 | 2,159 | 2,106 |
Vaccines | Influenza Vaccines |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 2,977 | 2,628 | 2,472 |
Consumer Healthcare |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 5,080 | 4,468 | 4,394 |
Consumer Healthcare | Allergy |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 734 | 612 | 617 |
Consumer Healthcare | Pain Care |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 1,213 | 1,093 | 1,051 |
Consumer Healthcare | Digestive Wellness |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 1,318 | 1,131 | 988 |
Europe |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 9,999 | 9,759 | 9,151 |
Europe | Pharmaceuticals |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 7,157 | 7,201 | 6,819 |
Europe | Pharmaceuticals | Dupixent |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 940 | 649 | 386 |
Europe | Pharmaceuticals | Neurology & Immunology |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 639 | 638 | 578 |
Europe | Pharmaceuticals | Aubagio |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 511 | 512 | 473 |
Europe | Pharmaceuticals | Rare Diseases |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 1,104 | 1,069 | 1,010 |
Europe | Pharmaceuticals | Cerezyme |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 239 | 244 | 249 |
Europe | Pharmaceuticals | Fabrazyme |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 228 | 223 | 200 |
Europe | Pharmaceuticals | Myozyme/Lumizyme |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 408 | 410 | 389 |
Europe | Pharmaceuticals | Oncology |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 239 | 327 | 299 |
Europe | Pharmaceuticals | Jevtana |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 33 | 112 | 187 |
Europe | Pharmaceuticals | Rare Blood Disorders |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 94 | 81 | 41 |
Europe | Pharmaceuticals | Alprolix |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 0 | 0 | 0 |
Europe | Pharmaceuticals | Eloctate |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 0 | 0 | 0 |
Europe | Pharmaceuticals | Core Assets |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 1,917 | 1,868 | 1,759 |
Europe | Pharmaceuticals | Lovenox |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 658 | 703 | 656 |
Europe | Pharmaceuticals | Toujeo |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 421 | 394 | 374 |
Europe | Pharmaceuticals | Plavix |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 101 | 115 | 126 |
Europe | Pharmaceuticals | Non-Core Assets |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 1,637 | 1,846 | 2,088 |
Europe | Pharmaceuticals | Lantus |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 426 | 474 | 537 |
Europe | Pharmaceuticals | Other non-core assets |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 1,129 | 1,285 | 1,451 |
Europe | Pharmaceuticals | Industrial sales |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 587 | 723 | 658 |
Europe | Vaccines |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 1,341 | 1,225 | 973 |
Europe | Vaccines | Polio/Pertussis/ Hib Vaccines |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 325 | 306 | 331 |
Europe | Vaccines | Influenza Vaccines |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 681 | 729 | 441 |
Europe | Consumer Healthcare |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 1,501 | 1,333 | 1,359 |
Europe | Consumer Healthcare | Allergy |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 55 | 49 | 51 |
Europe | Consumer Healthcare | Pain Care |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 555 | 515 | 481 |
Europe | Consumer Healthcare | Digestive Wellness |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 432 | 389 | 371 |
US |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 18,275 | 14,385 | 13,465 |
US | Pharmaceuticals |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 13,694 | 10,484 | 9,635 |
US | Pharmaceuticals | Dupixent |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 6,346 | 3,971 | 2,808 |
US | Pharmaceuticals | Neurology & Immunology |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 1,637 | 1,482 | 1,631 |
US | Pharmaceuticals | Aubagio |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 1,420 | 1,312 | 1,448 |
US | Pharmaceuticals | Rare Diseases |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 1,367 | 1,142 | 1,122 |
US | Pharmaceuticals | Cerezyme |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 194 | 173 | 177 |
US | Pharmaceuticals | Fabrazyme |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 471 | 395 | 406 |
US | Pharmaceuticals | Myozyme/Lumizyme |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 318 | 373 | 359 |
US | Pharmaceuticals | Oncology |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 515 | 410 | 368 |
US | Pharmaceuticals | Jevtana |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 275 | 253 | 246 |
US | Pharmaceuticals | Rare Blood Disorders |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 983 | 842 | 837 |
US | Pharmaceuticals | Alprolix |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 406 | 332 | 320 |
US | Pharmaceuticals | Eloctate |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 450 | 429 | 445 |
US | Pharmaceuticals | Core Assets |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 1,653 | 1,315 | 1,413 |
US | Pharmaceuticals | Lovenox |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 17 | 29 | 30 |
US | Pharmaceuticals | Toujeo |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 283 | 259 | 267 |
US | Pharmaceuticals | Plavix |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 9 | 9 | 10 |
US | Pharmaceuticals | Non-Core Assets |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 1,176 | 1,281 | 1,389 |
US | Pharmaceuticals | Lantus |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 757 | 861 | 929 |
US | Pharmaceuticals | Other non-core assets |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 412 | 410 | 438 |
US | Pharmaceuticals | Industrial sales |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 17 | 41 | 67 |
US | Vaccines |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 3,291 | 2,762 | 2,759 |
US | Vaccines | Polio/Pertussis/ Hib Vaccines |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 456 | 470 | 412 |
US | Vaccines | Influenza Vaccines |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 1,737 | 1,366 | 1,575 |
US | Consumer Healthcare |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 1,290 | 1,139 | 1,071 |
US | Consumer Healthcare | Allergy |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 439 | 371 | 361 |
US | Consumer Healthcare | Pain Care |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 212 | 196 | 181 |
US | Consumer Healthcare | Digestive Wellness |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 144 | 124 | 85 |
Other countries |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 14,723 | 13,617 | 13,425 |
Other countries | Pharmaceuticals |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 9,837 | 9,285 | 9,220 |
Other countries | Pharmaceuticals | Dupixent |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 1,007 | 629 | 340 |
Other countries | Pharmaceuticals | Neurology & Immunology |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 174 | 204 | 185 |
Other countries | Pharmaceuticals | Aubagio |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 100 | 131 | 124 |
Other countries | Pharmaceuticals | Rare Diseases |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 974 | 915 | 879 |
Other countries | Pharmaceuticals | Cerezyme |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 274 | 266 | 264 |
Other countries | Pharmaceuticals | Fabrazyme |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 239 | 226 | 211 |
Other countries | Pharmaceuticals | Myozyme/Lumizyme |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 232 | 220 | 200 |
Other countries | Pharmaceuticals | Oncology |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 198 | 175 | 131 |
Other countries | Pharmaceuticals | Jevtana |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 83 | 90 | 103 |
Other countries | Pharmaceuticals | Rare Blood Disorders |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 240 | 218 | 339 |
Other countries | Pharmaceuticals | Alprolix |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 98 | 82 | 146 |
Other countries | Pharmaceuticals | Eloctate |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 130 | 134 | 193 |
Other countries | Pharmaceuticals | Core Assets |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 2,819 | 2,585 | 2,409 |
Other countries | Pharmaceuticals | Lovenox |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 635 | 754 | 665 |
Other countries | Pharmaceuticals | Toujeo |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 413 | 316 | 292 |
Other countries | Pharmaceuticals | Plavix |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 873 | 805 | 777 |
Other countries | Pharmaceuticals | Non-Core Assets |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 4,409 | 4,515 | 4,849 |
Other countries | Pharmaceuticals | Lantus |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 1,076 | 1,159 | 1,195 |
Other countries | Pharmaceuticals | Other non-core assets |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 2,944 | 3,034 | 3,222 |
Other countries | Pharmaceuticals | Industrial sales |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 16 | 44 | 88 |
Other countries | Vaccines |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 2,597 | 2,336 | 2,241 |
Other countries | Vaccines | Polio/Pertussis/ Hib Vaccines |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 1,504 | 1,383 | 1,363 |
Other countries | Vaccines | Influenza Vaccines |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 559 | 533 | 456 |
Other countries | Consumer Healthcare |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 2,289 | 1,996 | 1,964 |
Other countries | Consumer Healthcare | Allergy |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 240 | 192 | 205 |
Other countries | Consumer Healthcare | Pain Care |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | 446 | 382 | 389 |
Other countries | Consumer Healthcare | Digestive Wellness |  |  |  |
Disclosure of geographical areas [line items] |  |  |  |
Net sales | € 742 | € 618 | € 532 |
[1] | Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfGeographicalAreasLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of revenue arising from the sale of goods. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 112 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_RevenueFromSaleOfGoods
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_SegmentsAxis=sny_PharmaceuticalsSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_DupixentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_NeurologyImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_AubagioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_RareDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_CerezymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_FabrazymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_MyozymeOrLumizymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_JevtanaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_RareBloodDisordersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_AlprolixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_EloctateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_CoreAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_LovenoxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_ToujeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_PlavixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_NonCoreAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_LantusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_OtherNonCoreAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_IndustrialSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=sny_VaccinesSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_PolioPertussisHibVaccinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_InfluenzaVaccinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_AllergyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_PainCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_DigestiveWellnessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |